Organon & Co. (OGN)
NYSE
Closed
Oct 7, 2026
Day's Range
13.7252 wk Range
5.69Overview - OGN - Organon & Co.
Key Statistics
Valuation
Enterprise Value
11.01B
P/E (Trailing)
‪17.60‬
P/E (Forward)
‪3.79‬
PEG Ratio
‪-0.65‬
Price / Sales (TTM)
‪0.58‬
Price / Book
‪3.58‬
EV / EBITDA
‪7.04‬
Profitability
Gross Margin
‪54.36%‬
Profit Margin
‪3.41%‬
Operating Margin
‪20.73%‬
Return on Assets
‪5.66%‬
Return on Equity
‪24.03%‬
Ownership
Shares Outstanding
262.60M
Float
242.98M
Short % of Shares Outstanding
‪7.23%‬
Held by Insiders
‪0.46%‬
Held by Institutions
‪84.81%‬
Price stats
Beta
‪1.51‬
50-Day Avg
‪13.64‬
200-Day Avg
‪10.63‬
Dividends
Payout Ratio
‪10.26%‬
Frequency
Quarterly
Analyst Consensus
5 analysts
Average price target
‪$ 11.25‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - OGN - Organon & Co.
Peers - OGN - Organon & Co.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NYSE.
Profile Summary - OGN - Organon & Co.
About
Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
